File(s) under permanent embargo
Belimumab (Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline)
journal contribution
posted on 2023-05-26, 10:28 authored by Ding, C, Jones, GBelimumab, the lead in a series of human monoclonal antibodies against the human protein B-lymphocyte stimulator (BLyS), is under development by Human Genome Sciences, Cambridge Antibody Technology and GlaxoSmithKline for the potential treatment of autoimmune diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). By January 2006, belimumab had completed phase II clinical trials in SLE and RA; a phase III clinical SLE trial is scheduled to begin later this year.
History
Publication title
Current Opinion in Investigational DrugsVolume
7Article number
5Number
5Pagination
464-472ISSN
1472-4472Publication status
- Published
Rights statement
restricted - published by ThompsonRepository Status
- Restricted
Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC